Novo Nordisk, a Danish multinational pharmaceutical company, introduced Brand Rybelsus, a tablet, containing oral Semaglutide, as a treatment for Type 2 diabetes in India in 2022.

Rybelsus is produced by Novo Nordisk and distributed by Abbott Pharmaceutical Company in India. Presently, it stands as the exclusive formulation of semaglutide available in India, in tablet form, and maintaining its status under patent protection.

Rybelsus pills are provided in three potency variations: 3mg, 7mg, and 14mg,  packaged in strips containing ten tablets each. The pricing structure is outlined as follows:

• Rybelsus 3mg with an MRP of 3170,
• Rybelsus 7mg is priced at 3520, and
• Rybelsus 14mg with an MRP of 3870.

However, it’s worth noting that the injectable alternatives, Ozempic and Wegovy, both featuring the semaglutide composition, are enjoying international popularity, and have yet to be introduced to the Indian market.

Meanwhile, other Indian pharmaceutical companies are diligently working at an accelerated pace to develop drugs with a semaglutide composition.

You can place your order for Rybelsus on our website or WhatsApp us at +91 – 98201 92284.